Richard Scheller joined 23andMe in 2015 as chief scientific officer and head of therapeutics, where he currently serves as a board director. Previously, Richard was executive vice president and head of Genentech Research and Early Development, and member of both the Genentech and Roche executive committees. At Genentech, Richard oversaw development of many of the first therapeutics cloned from small proteins. Prior to joining Genentech, Richard was a professor of biological sciences at Stanford University and was a Howard Hughes Medical Institute Investigator at the Stanford University School of Medicine from 1994 to 2001. Richard’s research elucidating the molecular machinery and regulatory mechanism that underlies neurotransmitter release earned him the 1997 U.S. National Academy of Sciences Award in Molecular Biology, the 2010 Kavli Prize in Neuroscience, and the 2013 Albert Lasker Basic Medical Research Award. Richard is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences, and a member of the National Academy of Medicine.